Trevi Therapeutics Appoints James V. Cassella, Ph.D. As Chief Development Officer
09/30/24, 11:11 PM
Location
new havenIndustry
biotechnology
Position
chief executive officer
president
chief development officer
Trevi Therapeutics, Inc announces the appointment of James V Cassella, PhD as Chief Development Officer. Dr Cassella, with over 35 years of experience in innovative publicly traded drug and product development companies, will join the executive management team to play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals.
Company Info
Location
195 church street
new haven, kentucky, united states
Additional Info
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough.